Statistical analysis title	Cohort 1, ACP: Fesoterodine 4 mg
Statistical analysis description	P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline number of incontinence episodes per 24 hours and baseline weight.
Comparison groups	Cohort 1, Active Comparator Phase: Fesoterodine 4 mg
Number of subjects included in analysis	33
Analysis specification	Pre-specified
Analysis type	Superiority
P-value	= 0.0496
Method	ANCOVA
Confidence interval	
Statistical analysis title	Cohort 1, ACP: Fesoterodine 8 mg
Statistical analysis description	P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline number of incontinence episodes per 24 hours and baseline weight.
Comparison groups	Cohort 1, Active Comparator Phase: Fesoterodine 8 mg

Number of subjects included in analysis	33
Analysis specification	Pre-specified
Analysis type	Superiority
P-value	= 0.0002
Method	ANCOVA
Confidence interval	
Statistical analysis title	Cohort 1, ACP: Oxybutynin
Statistical analysis description	P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline number of incontinence episodes per 24 hours and baseline weight.
Comparison groups	Cohort 1, Active Comparator Phase: Oxybutynin
Number of subjects included in analysis	35
Analysis specification	Pre-specified
Analysis type	Superiority
P-value	< .0001

Method	ANCOVA
Confidence interval	